Quotes on MAIA Biotechnology shares jumped 6.4% in U.S. premarket trading today, Tuesday, December 17, following a 10.0% surge the previous day. This came after the company announced that the FDA had <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/120/maia-biotechnology-granted-fda-rare-pediatric-disease?utm_source=in_materials">granted</a> a special designation to its drug for pediatric brain tumors. The designation <a href="https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs?utm_source=in_materials">came with</a> a voucher that can be redeemed to receive priority review for another drug or sold for hundreds of millions of dollars.

MAIA soars after its cancer drug receives FDA 'rare pediatric disease' designation

Shares of CNS Pharmaceuticals, a developer of treatments for brain cancer, surged more than 22% at the opening of trading on Monday. This follows a roughly 23% drop on Friday, June 14, when the company <a href="https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-announces-pricing-of-registered-direct-offering-and-concurrent-private-placement-39339608">announced</a> an agreement with private investors to sell $1.37 million worth of shares.

Oncology